We speak to these leading clinical researchers on the science behind the MiSight® 1 day contact lenses and how the findings of this study can be translated into clinical practice. Both Professor Debbie Jones and Professor Nicola Logan were investigators in the MiSight 1 day clinical trial, which is the longest-running soft contact lens study involving children.
We asked renowned myopia scientist and educator Professor Mark Bullimore about his paper on this topic, which clearly outlines that the benefits outweigh the risks with myopia control. Learn about why this analysis was explored, an overview of the paper and the take-home message for clinical practice, especially for childhood contact lens wear.
There’s a lot we already know about Essilor Stellest spectacle lenses for correcting and controlling myopia. This article explores recent published studies on visual fields, a crossover trial and the 3-year and 4-year clinical trial data.
We asked some key atropine questions of myopia thought leader Professor Mark Bullimore, who has published numerous landmark papers in the field, including his newest on the inconsistencies found in compounded atropine. Learn about the present and the future of atropine treatment for childhood myopia.
We had the privilege of chatting with Professor Karla Zadnik who is Principal Investigator of the CHAMP study on low-concentration atropine. Learn about how this study is a unique and important addition to our understanding of topical atropine in myopia control.
How do A-scan and optical biometry compare? How many measurements should you take and how frequently? Learn about instruments, measurement processes and how to use data on axial length in myopia management.
The HOYA MiYOSMART was the first of the new generation of myopia control spectacle lenses, with evidence for slowing myopia progression by at least half. Learn more about efficacy, the lens design, visual outcomes and more.
The MiSight 1 day clinical trial is the longest-running soft contact lens study among children, and is now reporting seven-year data. With questions explored including efficacy, cross over from control group to treatment and discontinuation, here’s some of what we’ve learnt along the way.
In this Q&A Interview, Optometrist Elizabeth Lumb reflects on the evolution of myopia management in the past five years through two ‘lenses’: as CooperVision’s Director of Global Professional Affairs, Myopia Management, and through the very personal experience of her now 12-year-old niece, Maddy.
Orthokeratology fitting to children is increasing in frequency worldwide, due to its volume of evidence for myopia control. Learn what data inputs are needed and how to best use your topographer for accurate ortho-k lens design.
